Drugs / Afluria
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07386509 | Mar 2020 → Nov 2022 | — | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00959049 | Sep → Dec 2009 | influenza | Seqirus | Completed | Met primary |
| Phase 43 trials · 1 met primary | ||||||
| Phase 4 | NCT05170399 | Sep 2022 → Aug 2026 overdue | lymphoma | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
| Phase 4 | NCT01688921 | Oct 2012 → Mar 2013 | influenza | PharmaJet, Inc. | Completed | Met primary |
| Phase 4 | NCT00735475 | Oct 2008 → Jan 2009 | influenza | Seqirus | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1/2 | NCT04956575 Comparator | Jul 2021 → Sep 2022 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01248208 Comparator | Sep 2010 → Sep 2011 | food allergy | Walter Reed Army Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01825200 Comparator | Mar → May 2013 | influenza | Protein Sciences Corporation | Completed | No outcome recorded |
| — | NCT00902278 Comparator | Oct 2008 → Apr 2016 | — | University of Massachusetts, Worcester | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Afluria | “we randomly assigned (1:1) healthy adults (aged 18-64 years) who attended one of four employee health clinics in the University of Colorado health system, with stratification...” PMID 24881803 ↗ May 201410“The safety and tolerability of Flublok(®), a purified recombinant hemagglutinin seasonal influenza vaccine, was compared to AFLURIA(®) in a randomized, blinded clinical trial” PMID 26529070 ↗ Nov 2015 “adults aged ≥18 years were randomly assigned to receive a single dose (6.25-200 µg) of mRNA-1010 or placebo (part 1) or an active comparator (Afluria; parts 2 and 3).” PMID 38934845 ↗ Feb 2025 “Afluria (age 9y and older)” NCT01248208 ↗ |
| Known as | CSL Limited Influenza Virus Vaccine | “CSL Limited Influenza Virus Vaccine (Afluria®)” NCT00735475 ↗ |
| Modality | Vaccine | “trivalent inactivated influenza vaccine Afluria” PMID 24881803 ↗ May 2014 |
| Route | Intramuscular | “given either intramuscularly with a needle-free jet injector (Stratis; PharmaJet, Golden, CO, USA) or with needle and syringe” PMID 24881803 ↗ May 2014 |